Thomas J. Schnitzer
Expertise in
1
conditions

Dr. Thomas J. Schnitzer

Rheumatology
345 E Superior St 9th Fl, 
Chicago, IL 
Offers Telehealth
54 Years of Experience
Expertise in
1
conditions
345 E Superior St 9th Fl, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Thomas Schnitzer is a Rheumatologist in Chicago, Illinois. Dr. Schnitzer has been practicing medicine for over 54 years is highly rated in 1 condition, according to our data. His top areas of expertise are Arthritis, Osteoporosis, Synovitis, Knee Replacement, and Hip Replacement.

His clinical research consists of co-authoring 94 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Harvard Medical School, 1971
Residency
Johns Hopkins University
Specialties
Rheumatology
Licenses
Neuromusculoskeletal Medicine, Sports Medicine in IL
Board Certifications
American Board Of Internal Medicine - Internal Medicine (Certified)
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

345 E Superior St 9th Fl, Chicago, IL 60611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Effects of Romosozumab on Bone Health in Women With Spinal Cord Injury and Osteoporosis
Effects of Romosozumab on Bone Health in Women With Spinal Cord Injury and Osteoporosis
Enrollment Status: Completed
Publish Date: September 24, 2025
Intervention Type: Drug
Study Drugs: Romosozumab, Alendronate
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Osteoarthritis Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Osteoarthritis Pain
Enrollment Status: Completed
Publish Date: July 17, 2024
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
A 2-stage, Adaptive, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate Dose and Treatment Effect of Pentosan Polysulfate Sodium Compared With Placebo in Participants With Knee Osteoarthritis Pain
A 2-stage, Adaptive, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate Dose and Treatment Effect of Pentosan Polysulfate Sodium Compared With Placebo in Participants With Knee Osteoarthritis Pain
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2024
Intervention Type: Drug
Study Drug: Pentosan Polysulfate Sodium
Study Phase: Phase 2/Phase 3
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind, 22-Week and 30-Week Open-label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of X0002 Spray in Relief of the Pain for Subjects With Osteoarthritis of the Knee
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind, 22-Week and 30-Week Open-label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of X0002 Spray in Relief of the Pain for Subjects With Osteoarthritis of the Knee
Enrollment Status: Completed
Publish Date: March 28, 2024
Intervention Type: Drug
Study Drug: X0002
Study Phase: Phase 3
Adaptations of the Brain in Chronic Pain With Opioid Exposure I
Adaptations of the Brain in Chronic Pain With Opioid Exposure I
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2024
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Chronic Low Back Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Chronic Low Back Pain
Enrollment Status: Completed
Publish Date: November 30, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Completed
Publish Date: November 22, 2023
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Osteoarthritis
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Osteoarthritis
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Osteoarthritis Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Osteoarthritis Pain
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drug: LY3556050
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Terminated
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drug: LY3556050
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Chronic Low Back Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Chronic Low Back Pain
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drug: LY3556050
Study Phase: Phase 2
Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain
Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain
Enrollment Status: Completed
Publish Date: October 05, 2023
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal®) to Provide Symptomatic Relief of Osteoarthritis of the Knee
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal®) to Provide Symptomatic Relief of Osteoarthritis of the Knee
Enrollment Status: Completed
Publish Date: August 09, 2023
Intervention Type: Drug
Study Drugs: Sodium Hyaluronate, Triamcinolone Hexacetonide
Study Phase: Phase 3
BRAIN MECHANISMS FOR CLINICAL PLACEBO IN CHRONIC PAIN: A Partially-Blind Randomized Clinical Trial of Placebo and Chronic Back Pain
BRAIN MECHANISMS FOR CLINICAL PLACEBO IN CHRONIC PAIN: A Partially-Blind Randomized Clinical Trial of Placebo and Chronic Back Pain
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug
Study Phase: Phase 4
Transcranial Magnetic Stimulation to Enhance Cortical Hippocampal Functional Connectivity as a Novel Means for Relieving Chronic OA Pain
Transcranial Magnetic Stimulation to Enhance Cortical Hippocampal Functional Connectivity as a Novel Means for Relieving Chronic OA Pain
Enrollment Status: Withdrawn
Publish Date: February 03, 2023
Intervention Type: Device
Study Phase: Not Applicable
Prevention of Bone Loss After Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy
Prevention of Bone Loss After Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy
Enrollment Status: Completed
Publish Date: June 29, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 16 Less Clinical Trials

94 Total Publications

International Spinal Cord Injury Fracture History Extended Data Set.
International Spinal Cord Injury Fracture History Extended Data Set.
Journal: Topics in spinal cord injury rehabilitation
Published: August 27, 2025
Similar Doctors
Expertise in
20
conditions
Dr. Sanford Baim
Rheumatology | Endocrinology
Expertise in
20
conditions
Dr. Sanford Baim
Rheumatology | Endocrinology

Cook County

1901 W Harrison St, 
Chicago, IL 
 (3.5 miles away)
312-633-7292
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sanford Baim is a Rheumatologist and an Endocrinologist in Chicago, Illinois. Dr. Baim is highly rated in 20 conditions, according to our data. His top areas of expertise are Hypercalcemia, Milk-Alkali Syndrome, Osteoporosis, and Hyperparathyroidism. Dr. Baim is currently accepting new patients.

Expertise in
14
conditions
Dr. Nadera J. Sweiss
Rheumatology
Expertise in
14
conditions
Dr. Nadera J. Sweiss
Rheumatology

The Board Of Trustees Of The University Of Illinois

1801 W Taylor St, 
Chicago, IL 
 (3.5 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nadera Sweiss is a Rheumatologist in Chicago, Illinois. Dr. Sweiss is highly rated in 14 conditions, according to our data. Her top areas of expertise are Sarcoidosis, Neurosarcoidosis, Rheumatoid Arthritis (RA), and Undifferentiated Connective Tissue Disease (UCTD).

Expertise in
18
conditions
Dr. Robert S. Katz
Rheumatology
Expertise in
18
conditions
Dr. Robert S. Katz
Rheumatology

Rheumatology Associates S.C.

1725 W Harrison St, 
Chicago, IL 
 (3.3 miles away)
312-226-8228
Languages Spoken:
English
See accepted insurances

Robert Katz is a Rheumatologist in Chicago, Illinois. Dr. Katz is highly rated in 18 conditions, according to our data. His top areas of expertise are Fibromyalgia, Arthritis, Rheumatoid Arthritis (RA), and Postmenopausal Osteoporosis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schnitzer's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile